Lead Product(s): Cerebral Dopamine Neurotrophic Factor
Therapeutic Area: Neurology Product Name: CDNF
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 17, 2020
Nanoform and Herantis have signed a letter of intent to collaborate to seek to enhance nasal drug delivery to the brain of Herantis’ CDNF and xCDNF therapies (Parkinson’s disease) using Nanoform’s proprietary biological nanoparticle technology.